106 related articles for article (PubMed ID: 35020699)
1. Retention With Medication for Opioid Use Disorder: The Role of the Primary Care Relationship.
Munger J; Back E
J Addict Med; 2022 Sep-Oct 01; 16(5):577-580. PubMed ID: 35020699
[TBL] [Abstract][Full Text] [Related]
2. Low barrier medication for opioid use disorder at a federally qualified health center: a retrospective cohort study.
Carter J; Li Z; Chen H; Greiner M; Bush C; Bhattacharya D; Poley S; Sachdeva N; Crowder JC; Feigal J
Addict Sci Clin Pract; 2022 Nov; 17(1):60. PubMed ID: 36335381
[TBL] [Abstract][Full Text] [Related]
3. Increasing Access to Buprenorphine for Opioid Use Disorder in Primary Care: an Assessment of Provider Incentives.
Kelley AT; Wilcox J; Baylis JD; Crossnohere NL; Magel J; Jones AL; Gordon AJ; Bridges JFP
J Gen Intern Med; 2023 Jul; 38(9):2147-2155. PubMed ID: 36471194
[TBL] [Abstract][Full Text] [Related]
4. The Role of Primary Care in the Initiation of Opioid Use Disorder Treatment in Statewide Public and Private Insurance.
Gertner AK; Rotter JS; Holly ME; Shea CM; Green SL; Domino ME
J Addict Med; 2022 Mar-Apr 01; 16(2):183-191. PubMed ID: 33973922
[TBL] [Abstract][Full Text] [Related]
5. "The Only Reason I Am Willing to Do It at All": Evaluation of VA's SUpporting Primary care Providers in Opioid Risk reduction and Treatment (SUPPORT) Center.
Williams EC; Frost MC; Danner AN; Lott AMK; Achtmeyer CE; Hood CL; Malte CA; Saxon AJ; Hawkins EJ
J Addict Med; 2024 May-Jun 01; 18(3):248-255. PubMed ID: 38385548
[TBL] [Abstract][Full Text] [Related]
6. Provider and Patient-panel Characteristics Associated With Initial Adoption and Sustained Prescribing of Medication for Opioid Use Disorder.
Cochran G; Cole ES; Sharbaugh M; Nagy D; Gordon AJ; Gellad WF; Pringle J; Bear T; Warwick J; Drake C; Chang CH; DiDomenico E; Kelley D; Donohue J
J Addict Med; 2022 Mar-Apr 01; 16(2):e87-e96. PubMed ID: 33973921
[TBL] [Abstract][Full Text] [Related]
7. Exploring the question of financial incentives for training amongst non-adopters of MOUD in rural primary care.
Haggerty T; Turiano NA; Turner T; Dekeseredy P; Sedney CL
Addict Sci Clin Pract; 2022 Dec; 17(1):72. PubMed ID: 36517926
[TBL] [Abstract][Full Text] [Related]
8. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
9. Factors associated with retention on medications for opioid use disorder among a cohort of adults seeking treatment in the community.
Biondi BE; Vander Wyk B; Schlossberg EF; Shaw A; Springer SA
Addict Sci Clin Pract; 2022 Mar; 17(1):15. PubMed ID: 35255967
[TBL] [Abstract][Full Text] [Related]
10. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
11. Nine-year substance use treatment outcomes with buprenorphine for opioid use disorder in a federally qualified health center.
Haddad M; Coman E; Bifulco L
Drug Alcohol Depend; 2024 Apr; 257():111252. PubMed ID: 38484404
[TBL] [Abstract][Full Text] [Related]
12. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
13. Supportive alternate site provision of buprenorphine: Overcoming barriers and improving patient outcomes.
Khan A; Khan Q; Kolb E
J Subst Abuse Treat; 2021 Apr; 123():108256. PubMed ID: 33612191
[TBL] [Abstract][Full Text] [Related]
14. From policy to practice: Pilot program increases access to medication for opioid use disorder in rural Colorado.
Sorrell TR; Weber M; Alvarez A; Beste N; Hollins U; Amura CR; Cook PF
J Subst Abuse Treat; 2020 Jul; 114():108027. PubMed ID: 32527514
[TBL] [Abstract][Full Text] [Related]
15. Geographic disparities in access to Medication for Opioid Use Disorder across US census tracts based on treatment utilization behavior.
Mitchell P; Samsel S; Curtin KM; Price A; Turner D; Tramp R; Hudnall M; Parton J; Lewis D
Soc Sci Med; 2022 Jun; 302():114992. PubMed ID: 35512612
[TBL] [Abstract][Full Text] [Related]
16. Association of MOUD ECHO Participation on Expansion of Buprenorphine Prescribing in Rural Primary Care.
Salvador JG; Myers OB; Bhatt SR; Jacobsohn V; Lindsey L; Alkhafaji RS; Rishel Brakey H; Sussman AL
Subst Abus; 2023 Oct; 44(4):282-291. PubMed ID: 37902036
[TBL] [Abstract][Full Text] [Related]
17. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs.
Winograd RP; Wood CA; Stringfellow EJ; Presnall N; Duello A; Horn P; Rudder T
J Subst Abuse Treat; 2020 Jan; 108():55-64. PubMed ID: 31277891
[TBL] [Abstract][Full Text] [Related]
18. "It's a place that gives me hope": A qualitative evaluation of a buprenorphine-naloxone group visit program in an urban federally qualified health center.
Lai S; Li E; Silverio A; DeBates R; Kelly EL; Weinstein LC
Subst Abus; 2021; 42(4):858-864. PubMed ID: 33492204
[No Abstract] [Full Text] [Related]
19. The impact of psychiatric comorbidity on treatment discontinuation among individuals receiving medications for opioid use disorder.
Friesen EL; Kurdyak P
Drug Alcohol Depend; 2020 Nov; 216():108244. PubMed ID: 32861134
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
Dowd WN; Barch DH; Seibert JH; Mark TL
J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
